TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22801836
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection of gadolinium and lidocaine hydrochloride, 2%, without epinephrine
Study: 20131296
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV cyclophosphamide (50 mg/kg daily for 4 days)
Study: 20131296
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (monthly IV cyclophosphamide at 750 mg/m2 for 6 months followed by quarterly IV cyclophosphamide for 2 years)
Study: 15954952
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg/kg/h
Study: 8750406
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg BID
Study: 8750406
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg BID
Study: 22964325
Drug: Long-pulse Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulse Nd:YAG 1064-nm laser treatment (8 sessions with a one-week interval)
Study: 22964325
Drug: Long-pulse Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulse Nd:YAG 1064-nm laser treatment (4 sessions with a one-week interval)
Study: 15523488
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement (86 mg/day) for 2 months (study 1)
Study: 15523488
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement (86 mg/day) for 3 months (study 2)
Study: 11772475
Drug: Routine methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine methadone treatment
Study: 15365537
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg once daily for 10 days
Study: 8529853
Drug: Verapamil (i.v.;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (i.v.; 10 mg)
Study: 8529853
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (s.l.; 5-10 mg)
Study: 6244079
Drug: Combined radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiation therapy and CCNU therapy (Group A: 26 cases)
Study: 6244079
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy alone (Group C: 50 cases)
Study: 23479393
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg po preoperatively followed by 200 mg po every eight hours for two days
Study: 21216197
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg per day)
Study: 17316648
Drug: Intrauterine lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine lidocaine (5-mL uterine instillation of 2% lidocaine) plus buccal misoprostol (200-microg tablet)
Study: 17316648
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) plus buccal misoprostol (200-microg tablet)
Study: 11099427
Drug: IV pentobarbital
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV pentobarbital (mean dose 3.75 ± 1.10 mg/kg)
Study: 11099427
Drug: IV midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV midazolam (mean dose 0.2 ± 0.03 mg/kg)
Study: 9768320
Drug: Topical decongestion
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decongestion
Study: 30698279
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 adjusted to maintain serum 25(OH)D above 30 ng/mL
Study: 28042304
Drug: Electroacupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture therapy for poststroke urinary incontinence (10 sessions)
Study: 28042304
Drug: Sham therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapies (10 sessions)
Study: 28042304
Drug: Sham therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapies
Study: 18637586
Drug: Dihydroartemisinin-piperaquine (40/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (40/320 mg, DP, group A)
Study: 18637586
Drug: Artemether-lumefantrine (20/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (20/120 mg tablets, AL, group B)
Study: 15930065
Drug: Computer-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive therapy (N=15)
Study: 15930065
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive therapy (N=15)
Study: 1881502
Drug: Effervescent cimetidine
Normalized name: cimetidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent cimetidine 800 mg
Study: 1881502
Drug: Maalox (liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox (liquid aluminium/magnesium hydroxide antacid)
Study: 30862658
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg once daily for 24 weeks
Study: 28098097
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa oil (2.5 mL, once daily, per orally) along with conservative management for 12 weeks
Study: 21797111
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg orally daily for six months plus carboplatin (AUC 7) intravenously every four weeks for up to six doses
Study: 21797111
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 7) intravenously every four weeks for up to six doses
Study: 19254585
Drug: fFN 0
Normalized name: (18F)FFNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: fFN 0 ng/mL
Study: 19254585
Drug: fFN 1-49
Normalized name: 18F-FFNP
DrugBank: Fluorofuranylnorprogesterone F-18 (DB15282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fFN 1-49 ng/mL
Study: 19254585
Drug: fFN 50-199
Normalized name: 18F-FFNP
DrugBank: Fluorofuranylnorprogesterone F-18 (DB15282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fFN 50-199 ng/mL
Study: 19254585
Drug: fFN >
Approvals — FDA: no, EMA: no, PMDA: no
Description: fFN > 200 ng/mL
Study: 8849352
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (5mg MTX/week plus 50 mg AZA/day to 7.5 mg MTX/week plus 100 mg AZA/day)
Study: 8849352
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 50-150 mg/day
Study: 8849352
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 5-15 mg/week
Study: 8849352
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment and Azathioprine (AZA)
Study: 2309991
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA) with propofol and alfentanil infusion
Study: 24473367
Drug: Normal-dose CTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose CTPA (100-kVp tube energy and 100-mL CM)
Study: 24473367
Drug: Low-dose CTPA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CTPA (80-kVp tube energy and 75-mL CM)
Study: 19946699
Drug: Non-WBV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-WBV treatment (stretching of the plantar flexors at end range of dorsiflexion for five 1-min bouts)
Study: 12669742
Drug: Alendronate 60
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 60 mg/day
Study: 8697058
Drug: Sibutramine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine doses varying from 1 to 30 mg
Study: 8697058
Drug: Sibutramine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (various doses)
Study: 2132640
Drug: Phosphatidylserine 25
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine 25 mg
Study: 2132640
Drug: Phosphatidylserine 50
Normalized name: phosphatidylserine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine 50 mg
Study: 2132640
Drug: Phosphatidylserine 75
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine 75 mg
Study: 443256
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of prednisolone
Study: 31361535
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg)
Study: 31361535
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pemetrexed and bevacizumab
Study: 19808128
Drug: Microplasmin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microplasmin 0.1 mg/kg
Study: 19808128
Drug: Microplasmin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microplasmin 0.5 mg/kg
Study: 19808128
Drug: Microplasmin 1
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 1 mg/kg
Study: 19808128
Drug: Microplasmin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microplasmin 1.5 mg/kg
Study: 19834019
Drug: Microplasmin 2
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 2 mg/kg
Study: 19808128
Drug: Microplasmin 1
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 1 mg/kg followed by infusion of 1 mg/kg
Study: 19808128
Drug: Microplasmin 1
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 1 mg/kg followed by infusion of 2 mg/kg
Study: 19808128
Drug: Microplasmin 1
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 1 mg/kg followed by infusion of 3 mg/kg
Study: 19808128
Drug: Microplasmin 1
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microplasmin 1 mg/kg followed by infusion of 4 mg/kg
Study: 11093025
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment for 10 seconds (0.069 ml of ozone)
Study: 11093025
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment for 20 seconds (0.138 ml of ozone)
Study: 11093025
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment for 10 seconds on S. mutans
Study: 11093025
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment for 10 seconds on S. sobrinus
Study: 9194719
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 400 mg 5 times a day for 3 weeks
Study: 3923081
Drug: Tube feeding
Normalized name: BAG,TUBE FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube feeding during radiation therapy
Study: 25355728
Drug: Rituximab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (both doses)
Study: 20196635
Drug: Antagonist group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonist group
Study: 15937757
Drug: PAmAb (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAmAb (0.3, 1.0, and 3.0 mg/kg intramuscular; 1.0, 3.0, 10, 20, and 40 mg/kg intravenous)
Study: 15937757
Drug: PAmAb (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAmAb (intramuscular and intravenous)
Study: 15937757
Drug: PAmAb (biological
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAmAb (biological activity)
Study: 8641910
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human granulocyte colony stimulating factor (G-CSF) at a dose of 300 micrograms subcutaneously, administered on Friday, Saturday, and Sunday during the radiotherapy period.
Study: 8641910
Drug: Large-field radiotherapy
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-field radiotherapy without G-CSF (Control group).
Study: 1503284
Drug: Methohexitone 9
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 9 mg.kg‐1.h‐1 for one hour (group M)
Study: 1503284
Drug: Methohexitone 9
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 9 mg.kg‐1.h‐1 with fentanyl 7 micrograms.kg‐1.h‐1 for one hour (group MF)
Study: 6742535
Drug: Flunitrazepam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.02 mg X kg‐1)
Study: 25327485
Drug: Acarbose 150
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 150 mg/day
Study: 17072954
Drug: 10% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucrose syrup + levodopa for 3 days (Group 1)
Study: 17072954
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for levodopa + 10% sucrose syrup for 3 days (Group 2)
Study: 17072954
Drug: 10% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucrose syrup + levodopa for 7 days (Group 3)
Study: 17072954
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for levodopa + 10% sucrose syrup for 7 days (Group 4)
Study: 8501336
Drug: Oral, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with full strength bicarbonate buffer (4 g)
Study: 8501336
Drug: Oral, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with half strength bicarbonate buffer (2 g)
Study: 8501336
Drug: Full strength
Normalized name: Dakins Full Strength Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full strength buffer without vaccine
Study: 8501336
Drug: Half strength
Normalized name: Dakins Half Strength Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half strength buffer without vaccine
Study: 3471750
Drug: Imipenem 500
Normalized name: imipenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 500 mg
Study: 3471750
Drug: Latamoxef 1
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latamoxef 1 g
Study: 29280043
Drug: Lapatinib, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 2 weeks
Study: 29280043
Drug: Lapatinib, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 18 weeks plus weekly paclitaxel
Study: 26321318
Drug: Riluzole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (50 mg orally, twice daily)
Study: 18277878
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group training protocol (exercise therapy, back school, behavioral principles)
Study: 16547634
Drug: Betamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (8 mg/day)
Study: 16547634
Drug: Methylprednisolone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (8 mg/day)
Study: 8356591
Drug: TMP (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP (160 mg)‐SMX (800 mg) twice daily three days per week (group B)
Study: 8356591
Drug: TMP (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP (160 mg)‐SMX (800 mg) twice daily seven days per week (group C)
Study: 3306440
Drug: Caroverine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroverine (120 mg/day)
Study: 3306440
Drug: Meprobamate (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meprobamate (2,400 mg/day)
Study: 3306440
Drug: Caroverine (2.5-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroverine (2.5-5.0 mg/kg, infusional application)
Study: 15816793
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg/day in week 1, 16 mg/day in week 2, 24 mg/day in week 3)
Study: 12873937
Drug: Isoflurane inhaled
Normalized name: isoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhaled anesthesia
Study: 11176472
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bethanechol
Study: 3557757
Drug: Cephradine 2
Normalized name: cephradine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine 2 g
Study: 23211012
Drug: Placebo-solution (placebo-group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-solution (placebo-group)
Study: 19734766
Drug: Tunnelled intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tunnelled intravitreal injection
Study: 19734766
Drug: Straight intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straight intravitreal injection
Study: 17392720
Drug: Five-drug cocktail
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug cocktail (Inje cocktail)
Study: 15042543
Drug: Iron dextran,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran, 1,000 mg IV
Study: 11556875
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor therapy
Study: 11717931
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine Zeng Sheng Ping for severe dysplasia
Study: 11717931
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of riboflavin Calcium for mild dysplasia
Study: 10150222
Drug: Nisoldipine once
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine once daily (up to 20 mg/day)
Study: 10150222
Drug: Nisoldipine twice
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine twice daily (up to 20 mg/day)
Study: 10150222
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (before and after nisoldipine)
Study: 2574728
Drug: Nisoldipine once
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine once daily
Study: 29187151
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2.5 μg/kg (group D)
Study: 29187151
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 6 mg/kg (group K)
Study: 29187151
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 μg/kg and oral ketamine 3 mg/kg (group DK)
Study: 25924803
Drug: Corticosteroids (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (1 mg/kg/day i.v. methylprednisolone intraoperatively and at postoperative days 1-5)
Study: 23739650
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/simvastatin 20 mg
Study: 11473139
Drug: Snapshot methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snapshot methods (same-day telephone interviews or one-off weekly diaries)
Study: 9409501
Drug: No oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oxygen therapy (Control)
Study: 7773823
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg in 20 ml NaCl)
Study: 7773823
Drug: Bupivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (20 ml, 0.375%)
Study: 7773823
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupivacaine and morphine
Study: 7773823
Drug: Saline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (20 ml, control group)
Study: 344003
Drug: Desoximetasone emollient
Normalized name: Desoximetasone
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desoximetasone emollient cream (0.25 percent)
Study: 344003
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate cream (0.1 percent)
Study: 22967016
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy during high-dose chemotherapy
Study: 15616083
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of meperidine (150 mg, range 75-200 mg)
Study: 10443885
Drug: Initial monthly
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial monthly scanning cohort
Study: 1905799
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with oral penicillin V
Study: 1905799
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with placebo followed by penicillin V
Study: 23317960
Drug: 6-month thrice-weekly
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month thrice-weekly directly observed treatment (DOT) regimen for tuberculous peripheral adenopathy
Study: 23317960
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment up to 9 months
Study: 23317960
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without additional treatment